L Patrick Gage becomes chair of Tetraphase board
This article was originally published in Scrip
Executive Summary
Clinical stage tetracycline antibiotics developer, Tetraphase, has appointed Dr L Patrick Gage chair of its board of directors. Dr Gage currently serves on the boards of several life science companies, including as chair of Cytokinetics. He served as president of research at Wyeth/American Home Products Corporation until 2002.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.